Here is Why Growth Investors Should Buy McKesson (MCK) Now
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson (MCK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Q2 Earnings and Revenues Beat Estimates
McKesson (MCK) came out with quarterly earnings of $7.07 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.23 per share a year ago.
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
